MGP
NBIX icon

Metis Global Partners’s Neurocrine Biosciences NBIX Stock Holding History

Metis Global Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,113
Closed -$278K – 734
2026
Q1 		$278K Sell
2,113
-128
-6% -$17K 0.01% 652
2025
Q4 		$318K Sell
2,241
-104
-4% -$15.1K 0.01% 649
2025
Q3 		$329K Sell
2,345
-107
-4% -$14.5K 0.01% 651
2025
Q2 		$308K Sell
2,452
-640
-21% -$73.4K 0.01% 655
2025
Q1 		$342K Buy
3,092
+544
+21% +$68.9K 0.01% 645
2024
Q4 		$348K Buy
2,548
+104
+4% +$12.9K 0.01% 642
2024
Q3 		$282K Buy
2,444
+203
+9% +$27.8K 0.01% 682
2024
Q2 		$309K Buy
2,241
+30
+1% +$4.11K 0.01% 650
2024
Q1 		$305K Sell
2,211
-19
-0.9% -$2.6K 0.01% 656
2023
Q4 		$294K Sell
2,230
-131
-6% -$15.1K 0.01% 647
2023
Q3 		$266K Buy
2,361
+106
+5% +$11.2K 0.01% 654
2023
Q2 		$213K Buy
2,255
+176
+8% +$17.2K 0.01% 671
2023
Q1 		$210K Buy
+2,079
New +$216K 0.01% 627

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Metis Global Partners's NBIX Position: Q2 2026 in Review

Metis Global Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 2,113 shares — an estimated $278K sold.

Metis Global Partners first reported a position in NBIX in Q1 2023 and held it in 13 quarters. The position peaked at $348K in Q4 2024. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Metis Global Partners reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Metis Global Partners sold 2,113 Neurocrine Biosciences shares in Q2 2026, an estimated $278K.
  • Metis Global Partners first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 13 quarters.
  • Metis Global Partners's Neurocrine Biosciences position peaked at $348K in Q4 2024.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.